EDUCATION
AND TRAINING
BA in Geology, Williams College, Williamstown,
Massachusetts, 1985
MD, Univeristy of Colorado School of Medicine,
Denver, Colorado, 1992
Internship and Residence in Internal Medicine,
University of California at San Francisco, San
Francisco, California 1995
Hospitalist Fellow in Internal Medicine,
University of California at San Francisco, San
Francisco, California 1996
Chief Resident in Internal Medicine, University
of California at San Francisco, San Francisco,
California 1997
MS in Epidemiology, University of Washington,
Seattle, Washington 2000
Fellowship in Pulmonary and Critical Care
Medicine, University of Washington, Seattle,
Washington 2001
|
CURRENT RESEARCH
INTERESTS
My research focuses on assessing predictors of
survival in patients with cystic fibrosis and
generating mathmatical models to predict survival
in these patients. I am also involved in studying
the changes of quality of life of patients with
cystic fibrosis through time and integrating this
information into the decision of these patients
to pursue lung transplantation. Additional areas
of interest have included the long-term
mechanical ventilation outside of the intensive
care unit and the epidemiology of acute
respiratory distress syndrome. In addition to
work in pulmonary and critical care epidemiology,
I am the Associate Medical Director of the Cystic
Fibrosis Therapeutics Development Network, a
clinical trials network involving academic
medical centers across the nation evaluating new
and existing therapies for the treatment of
patients with cystic fibrosis.
REPRESENTATIVE PUBLICATIONS
Goss CH, Aitken ML, Otto K, Rubenfeld GD.
Detecting Stenotrophomonas maltophilia does not
decrease survival in patients with Cystic
Fibrosis. Am J Respir Crit Care Med. 2002 Aug
1;166(3):356-61
Nathens AB, Neff MJ, Goss CH, Maier RV, and
Rivara FP. The effect of an older sibling and
birth interval on the risk of childhood injury.
Inj Prev, 2000; 6(3)219-23.
Goss CH, Mayer-Hamblett N, Kronmal RA, and Ramsey
BW. The Cystic Fibrosis Therapeutics Development
Network (CF TDN): A paradigm of a clinical trials
network for genetic and orphan diseases. Adv Drug
Deliv Rev. 2002 Dec 5;54(11):1505-28.
Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss
CH, Aitken ML. Developing Cystic Fibrosis lung
transplant referral criteria using predictors of
two year survival.Am J Respir Crit Care Med. 2002
Dec15;166(12 Pt 1):1550-5.
Goss CH. Airway clearance in cystic fibrosis
Respir Care. 2003. Jan; 48(1):20-1.
Goss CH, Brower RG, Hudson LD, Rubenfeld GD.
Incidence of acute lung injury in the United
States (in press, Critical Care Medicine).
|
